TickerFacts.

Zura Bio Ltd (ZURA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$75.20M
Year ended 2025-12-31
2024-12-31: -$55.18M2025-12-31: -$75.20M-$75.20M
2024-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$75.20Mn/m2026-03-19, From 2025-01-01
2024-12-31-$55.18Mn/a2026-03-19, From 2024-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Zura Bio Ltd (ZURA)2025-12-31-$75.20Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$35.92Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31-$87.21Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$41.55Mn/m
Quince Therapeutics, Inc. (QNCX)2025-12-31-$57.93Mn/m
aTYR PHARMA INC (ATYR)2025-12-31-$76.96Mn/m
Inhibrx Biosciences, Inc. (INBX)2025-12-31-$132.54Mn/m
Tenaya Therapeutics, Inc. (TNYA)2025-12-31-$84.89Mn/m
ImageneBio, Inc. (IMA)2025-12-31-$48.05Mn/m

Compare ZURA, LCTX, ARTV, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗